BioSpace News Archive

CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

Mersana Therapeutics, Inc. announced that on August 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 32,475 shares of its common stock, to 8 new employees whose employment commenced in July 2022.

Rain Therapeutics Inc., a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

Eledon Pharmaceuticals, Inc. announced that it plans to release financial results for the second quarter ended June 30, 2022 on Thursday, August 11, after the close of trading.

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Freeline Therapeutics Holdings plc announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones and four other newly hired employees non-statutory options to purchase an aggregate of 240,000 and 35,250 of the Company’s ordinary shares, respectively.

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Synthetic Biologics, Inc. announced that Company’s management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022.

Cytokinetics, Incorporated reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million, or $0.86 per share.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, provided a corporate update and reported financial results for the second quarter ended June 30, 2022.